Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noram Lithium Corp V.NRM

Alternate Symbol(s):  NRVTF

Noram Lithium Corp. is Canadian junior exploration and development company. The Company is focused on advancing its Zeus Lithium Project (Zeus) to production in Nevada. The Zeus property is approximately halfway between Las Vegas and Reno; and within two kilometers of Albemarle Corporation’s lithium brine producing operations (Silver Peak Mine). The property is comprised of 1,133 hectares which is the equivalent of 2,800 acres. Zeus consists of approximately 146 placer claims and 136 lode claims. The perimeter of the Zeus claims is located within 1-mile (1.6 kilometers) of Albemarle Corporation's (Albemarle's) lithium brine operations. Lithium is produced at Albemarle’s plant from deep wells that pump brines from the basin beneath the Clayton Valley playa.


TSXV:NRM - Post by User

Bullboard Posts
Comment by webpiloton Dec 06, 2007 5:45pm
181 Views
Post# 13928429

RE: NEWS OUT

RE: NEWS OUTA Class 1 Review is for a period of 3 months. A Class 2 Review is for a period of 6 months, and usually is for resolving the final labeling of the drug. Everything appears to very positive regarding Kiacta. "We look forward to further productive interactions with the FDA as we enter late-stage discussions on our marketing application," said Dr. Francesco Bellini, Neurochem Inc.'s Chairman, President and CEO. As you see, Bellini states the the discussions are concerning marketing Kiacta.
Bullboard Posts